To cite this paper use one of the standards below:
This work aimed to obtain an overview between dissolution studies and drugs administered as oral suspension in Brazil and USA in January 2019. Anvisa and FDA homepages were searched in order to identify reference, generic and interchangeable similar medicines in Brazil or NDA and ANDA in USA. Data about dissolution studies for oral suspension was carried out in Pharmacopeias. Forty-six drugs were registered by Anvisa, being 47 reference, 173 generic and 114 interchangeable similar medicines; and 90 drugs by FDA, being 235 Abreviatted New Drug Application and 111 New Drug Application medicines. Out of 46 and 90, only six (13%) and 15 (17%) drugs as oral suspension had a pharmacopeial dissolution test, corresponding to 70 (20.9%) and 82 (23.7%) products in Brazil and USA, respectively. This scarcity of dissolution test information can compromise pharmaceutical development, stability studies, routine quality control, scale-up and post-approval changes, interchangeability evaluation, and consequently, therapeutic equivalence.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper